Biosimilar Manufacturing solution center

  1. Maximizing Uptime With Equipment Health Checks 3/31/2026

    Modern bioprocessing demands continuous awareness of equipment performance. Learn how proactive health checks, real‑time monitoring, and structured troubleshooting help detect issues early.

  2. Building Bulletproof Bioprocesses With Equipment Qualification 3/31/2026

    Consistent equipment performance is critical for compliant biomanufacturing. Learn how lifecycle‑based, risk‑driven qualification strategies can reduce risk and improve efficiency.

  3. Scale-Up Of AAV Production In Fixed-Bed Bioreactors 3/31/2026

    Consistent AAV production is critical for manufacturing. See how aligned strategies deliver comparable cell growth, metabolic trends, and rAAV5 titers from development through production.

  4. Cost Modeling Analysis Of AAV And LV Manufacturing 3/31/2026

    Manufacturing scale plays a critical role in viral vector economics. Compare AAV and LV production scenarios to gain insight into how intermediate-scale strategies can reduce cost and risk.

  5. Immobilized Enzymes Promise Alternative To Cyanogen Bromide's Toxicity 3/27/2026

    Proteases may be more expensive up front, but the benefits of cutting out a highly toxic substance quickly add up when disposal and environmental safety costs go down.

  6. Ever Wonder What Running A $50B Capital Facilities Project Feels Like? 3/23/2026

    Eli Lilly and Company's projects in the U.S. include greenfield sites where little infrastructure exists. Here's how the company's approaching the challenge.

  7. Generative AI Can Write The Code, But Who Builds In The Quality? 3/23/2026

    Code democratization demands a return to the fundamentals of quality in pharmaceutical and regulated environments.

  8. Aseptic Filling By Design: Shaping The Future Of Drug Manufacturing 3/20/2026

    Modern therapies demand higher sterility assurance and flexible operations. Discover how advanced contamination control, barrier systems, and automation strengthen quality and support faster delivery.

  9. UK's Decentralized Manufacturing Could Be A Revolution; Mind The Risk 3/20/2026

    Decentralized manufacture will only improve patient outcomes if the pharmaceutical quality system at the control site is strong enough to carry the weight of the network.

  10. All The Ways Global Biopharma Still Grapples With Annex 1 3/19/2026

    Biopharma companies can't consistently meet Annex 1 expectations. At the heart of the problems, regulators have shifted the burden of proof to manufacturers.